Cala Health Hopes To Jolt Essential Tremor Market With Wrist-Worn Non-Invasive Stimulation
Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.
You may also be interested in...
News We’re Watching: New CDC Director, Endologix Study Success, Hospital Closure Linked To Ransomware
This week, North Carolina health secretary Mandy Cohen was named the new head of the CDC; Congress debated PAHPA reauthorization; Cala Health launched a Parkinson’s Disease wearable; and IHealth.io was fined for consumer privacy violations.
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.